Eisenhauer T, Armstrong V W, Schuff-Werner P, Schütz E, Thiery J, Scheler F, Seidel D
Department of Nephrology, University Hospital, Göttingen, Federal Republic of Germany.
ASAIO Trans. 1989 Jul-Sep;35(3):580-3. doi: 10.1097/00002480-198907000-00133.
Extracorporeal low density lipoprotein (LDL)-apheresis offers an adjunctive therapy to diet and drug treatment for reducing LDL concentrations in patients with excessively high cholesterol levels and those at high coronary risk. After nearly 4 years experience with the heparin-induced extracorporeal LDL/fibrinogen precipitation (HELP) system, based on heparin induced LDL precipitation at acidic pH, over 7,000 single aphereses have been performed on more than 100 patients in several clinics. Due to the simultaneous removal of LDL and fibrinogen, regular HELP-LDL-apheresis can normalize hemorrheologic parameters, thus explaining the observation of a rapid and lasting clinical improvement in signs and symptoms of coronary heart disease (CHD). The use of Simvastatin in combination with HELP significantly augments the reduction in LDL cholesterol to a level where regression of atherosclerotic lesions might be expected.
体外低密度脂蛋白（LDL）吸附术为饮食和药物治疗提供了一种辅助疗法，用于降低胆固醇水平过高以及冠心病高危患者的LDL浓度。在使用基于肝素诱导LDL在酸性pH下沉淀的肝素诱导体外LDL/纤维蛋白原沉淀（HELP）系统近4年的经验之后，几家诊所已对100多名患者进行了7000多次单次吸附治疗。由于同时去除了LDL和纤维蛋白原，常规的HELP-LDL吸附术可使血液流变学参数正常化，从而解释了冠心病（CHD）体征和症状迅速且持久的临床改善现象。辛伐他汀与HELP联合使用可显著增强LDL胆固醇的降低程度，达到预期可使动脉粥样硬化病变消退的水平。
